To assess the difference between Ki-67 and HER2 status in HR+ cancers, luminal tumors were further classified after inclusion of HR+/HER2+ tumors [31,32] into luminal 1 and 2, with the former being HR+ and HER2- (luminal), and the later being HR+ and HER2+. The gene discussed is HR; the disease is cancer.